REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Regulation FD Disclosure
Item 7.01 REGULATION FD DISCLOSURE

Revance Therapeutics, Inc. (the “Company”) issued a press release on December5, 2017, announcing clinical results from its SAKURA 1 and SAKURA 2 Phase 3 pivotal trials of DaxibotulinumtoxinA for Injection (RT002) for the treatment of glabellar (frown) lines. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

During a conference call and webcast scheduled to be held at 5:00 a.m. Pacific Time on December5, 2017, Company management will discuss the results from the study. The slide presentation for the conference call and webcast is furnished as Exhibit 99.2 hereto and is incorporated by reference herein.

The information in this Item 7.01 of this current report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 7.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Revance Therapeutics, Inc. Exhibit
EX-99.1 2 d462936dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Revance’s RT002 Meets Primary and All Secondary Endpoints,…
To view the full exhibit click here

About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.